Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Genomic Health Announces Publication of a Study Comparing Oncotype DX(R) and Adjuvant! Online in Node-Negative and Node-Positive Hormone Receptor-Positive Breast Cancer Patients
September 18th, 2008
Genomic Health, Inc. (NASDAQ:GHDX) announced the publication of positive results from a study indicating that the Oncotype DX(R) Recurrence Score(R) provides additional prognostic information beyond Adjuvant! Online (AO) for breast cancer patients with negative nodes or up to three positive nodes. The study, published in the September 1st issue of the Journal of Clinical Oncology, showed that the Recurrence Score result was a highly significant predictor of recurrence in both node-negative disease (p=3D0.0007) and node-positive disease (p=3D0.0004). Oncotype DX measures the expression of 21 genes of an individual tumor to generate a Recurrence Score result that...
Source: Women's Health Weekly (2008-09-18)
|
